Abstract Prior Presentation & Publication Policies

Abstract Policies

Upon submission of an abstract to the 2010 Breast Cancer Symposium, the First Author must agree to the following Abstract Policies on behalf of all parties involved with the abstract. The First Author is also responsible for communicating these policies to all co-authors. If any of these policies are violated, the involved abstract may be removed from the Symposium.

• Confidentiality Policy
• Conflict of Interest Policy
• Prior Presentation or Publication Policy

Confidentiality Policy

All First Authors and Sponsors of submitted abstracts must agree to the following:

Submitted Abstracts are considered Confidential and are subject to the Abstract Policies of the Symposium from the time of submission.* For a study to be eligible for presentation, information contained in the abstract, as well as additional data and information to be presented about the study, may not be disclosed before the findings have been publicly released in conjunction with the Symposium.
 
The Abstract Policies require that, prior to the abstract being publicly released by the Symposium, the author, coauthors, and sponsor of the research not:

1)      publish the information or provide it to others who may publish it,
2)      release the findings to news media, or
3)      use the information for trading in the securities of any issuer, or provide it to others 
         who may use it for securities trading purposes. 

The First Author is responsible for conveying this information to all parties.

*The one exception to these policies applies to abstract information that has been previously made public through presentation at another meeting.  In these cases, confidentiality applies only to any updated information.

There is a formal exception process in place to address public disclosure in advance of the Symposium due to Securities and Exchange Commission requirements.   To file an official Abstract Policy Exception Request, please contact ASCO directly.

Conflict of Interest Policy

In compliance with standards established by the ASCO Conflict of Interest Policy (J Clin Oncol. 2006 Jan 20;24[3]:519–521) and the Accreditation Council for Continuing Medical Education (ACCME), ASCO strives to promote balance, independence, objectivity, and scientific rigor through disclosure of financial and other interests, and identification and management of potential conflicts. According to the Society’s Conflict of Interest Policy, the following financial and other relationships must be disclosed:  employment or leadership position, advisory role, stock ownership, honoraria, research funding, expert testimony, and other remuneration (J Clin Oncol. 2006 Jan 20;24[3]:520).

For clinical trials that began accrual on or after April 29, 2004, ASCO’s Policy places some restrictions on the financial relationships of principal investigators (J Clin Oncol. 2006 Jan 20;24[3]:521). If a principal investigator holds any restricted relationships, his or her abstract may be ineligible for placement in the 2009 Breast Cancer Symposium unless the Ethics Committee grants an exception. When a principal investigator has restricted relationships, the First Author will be prompted to apply to the Ethics Committee for an exception to the Policy. Exception request materials may be uploaded as part of the abstract submission process or e-mailed to coi@asco.org.

NIH-funded trials are exempt from the Policy restrictions. ASCO will collect information on accrual initiation date, financial relationships of the principal investigator, and NIH funding upon abstract submission. It is the responsibility of the First Author to obtain disclosure information from all coauthors and to provide all disclosure of such interests and relationships through the Abstract Submitter program. Copies of the Disclosure Form can be sent to coauthors for completion and returned before submission of the abstract.

For more information on the ASCO Conflict of Interest Policy, the principal investigator restrictions, and applying for an exception to the Policy, please visit www.asco.org/conflictofinterest.

Prior Presentation or Publication Policy

If you intend to submit an abstract for the Annual Meeting of a co-sponsoring organization, please read below the policy regarding whether or not abstracts presented at the Breast Cancer Symposium will be eligible for presentation at the co-sponsors’ Annual Meeting.

ASBD -   An abstract submitted for presentation at the 2010 Breast Cancer Symposium may also be submitted for presentation at the 2010 ASBD Annual Meeting.

The American Society of Breast Surgeons -  An abstract submitted for presentation at the ASCO 2010 Breast Cancer Symposium may not be submitted for presentation at the American Society of Breast Surgeons 2010 Annual Meeting.

ASCO – An abstract submitted for presentation at the 2010 Breast Cancer Symposium may also be submitted for presentation at the 2011 ASCO Annual Meeting.   

Note:  If your abstract is to be considered for presentation at the ASCO Annual Meeting, you are encouraged to submit updated data.  You will also need to resubmit your abstract using ASCO’s 2011 Annual Meeting Online Submitter.

ASTRO - Abstract submissions of papers presented at the Breast Cancer Symposium will be accepted for consideration in ASTRO's 2010 Annual Meeting Scientific Program.

NCBC - Abstract submissions of papers presented at the Breast Cancer Symposium will be accepted for consideration in NCBC's 2010 Annual Meeting Scientific Program.

SSO -  An abstract submitted for presentation at the Breast Cancer Symposium may also be submitted for presentation at the 2010 SSO Annual Meeting. 

Changes to Abstracts

First Authors may request corrections to rectify errors (i.e., typos, misspellings) within abstract submissions. Requests must be submitted by September 1, 2010.

	Requests for changes must be sent by the First Author to abstracts@asco.org.
	Please call 571-483-1400 or 1-800-516-5850 with any questions.

• Please include the abstract ID, title, and an explanation of the changes to be made to the original text.
• Updates to original data will not be permitted, as changes are permissible only for the correction of errors.

Withdrawal of Abstracts

If a First Author chooses to withdraw his or her abstract for any reason, a request must be submitted by September 1, 2010

	Requests may be sent via e-mail to abstracts@asco.org.
	Requests may also be made by phone at 571-483-1400 or 1-800-516-5850.

• Additionally, a written request may be sent to the ASCO Education, Science, and Professional Development Department, 2318 Mill Road, Suite 800, Alexandria, VA 22314.
• Any abstract withdrawal requests received after this date will be considered on a case-by-case basis and cannot be assured removal from the Meeting Proceedings.